Press Releases

Press Releases

Filters
Viatris Reports First Quarter 2025 Results and Reaffirms 2025 Outlook
Viatris Announces Positive Results from Phase 3 Study of Investigational XULANE LO™ Low Dose Patch for Birth Control in Women of Childbearing Potential
Viatris Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Novel Fast-Acting Meloxicam (MR-107A-02) for the Treatment of Moderate-to-Severe Acute Pain
Viatris Announces Quarterly Dividend
Viatris Announces Appointments of Frank D'Amelio and Michael Severino, M.D., to the Company's Board of Directors
Viatris to Present at the BofA Securities 2025 Healthcare Conference
Viatris Files Supplemental New Drug Applications to Japan's Ministry of Health, Labor and Welfare for the Approval of EFFEXOR® for the Treatment of Generalized Anxiety Disorder
Viatris Appoints Hemanth J. Varghese as Chief Strategy Officer
Viatris Statement on Nationwide Settlement to Resolve Opioid-Related Claims
Viatris to Report First Quarter 2025 Financial Results on May 8, 2025
Displaying 31 - 40 of 184